250 related articles for article (PubMed ID: 25610713)
1. Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.
Xia GH; Zeng Y; Fang Y; Yu SR; Wang L; Shi MQ; Sun WL; Huang XE; Chen J; Feng JF
Cancer Biol Med; 2014 Dec; 11(4):270-6. PubMed ID: 25610713
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Fan Y; Huang ZY; Yu HF; Luo LH
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
[TBL] [Abstract][Full Text] [Related]
4. Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Kwon BS; Park JH; Kim WS; Song JS; Choi CM; Rho JK; Lee JC
Tuberc Respir Dis (Seoul); 2017 Apr; 80(2):187-193. PubMed ID: 28416959
[TBL] [Abstract][Full Text] [Related]
5. [Retreatment with epidermal growth factor receptor inhibitor after initial failure in advanced non-small cell lung cancer].
An T; Huang Z; Wang Y; Wang Z; Bai H; Wang J
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):261-5. PubMed ID: 21426670
[TBL] [Abstract][Full Text] [Related]
6. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
7. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
[TBL] [Abstract][Full Text] [Related]
8. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Lee CK; Davies L; Wu YL; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu YK; Gralla RJ; Gebski V; Mok T; Yang JC
J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376144
[TBL] [Abstract][Full Text] [Related]
10. Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.
Tang M; Wang S; Zhao B; Wang W; Zhu Y; Hu L; Zhang X; Xiong S
Med Sci Monit; 2019 Nov; 25():8430-8437. PubMed ID: 31704907
[TBL] [Abstract][Full Text] [Related]
11. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Duan JC; An TT; Wu MN; Yang L; Bai H; Wang ZJ; Wang YY; Zhuo ML; Zhao J; Wang SH; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2012 May; 35(5):323-8. PubMed ID: 22883988
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.
Wan C; Zhang Y; Liu P; Mei X; Cheng G; Pang J; Chen S; Xu J; Malhotra J; Qian H; Du Y
J Thorac Dis; 2023 Oct; 15(10):5648-5657. PubMed ID: 37969256
[TBL] [Abstract][Full Text] [Related]
14. Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer.
Song Z; Yu X; He C; Zhang B; Zhang Y
J Thorac Dis; 2013 Aug; 5(4):400-5. PubMed ID: 23991294
[TBL] [Abstract][Full Text] [Related]
15. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
Azuma K; Hirashima T; Yamamoto N; Okamoto I; Takahashi T; Nishio M; Hirata T; Kubota K; Kasahara K; Hida T; Yoshioka H; Nakanishi K; Akinaga S; Nishio K; Mitsudomi T; Nakagawa K
ESMO Open; 2016; 1(4):e000063. PubMed ID: 27843623
[TBL] [Abstract][Full Text] [Related]
17. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab combined with chemotherapy is beneficial for patients with advanced non-small cell lung cancer after EGFR-tyrosine kinase inhibitors failure.
Zhang F; Yu Y; Xing L; Chen M
Int J Clin Exp Med; 2015; 8(9):16140-8. PubMed ID: 26629127
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
20. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
